{"id":899061,"date":"2025-10-22T21:56:14","date_gmt":"2025-10-23T01:56:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\/"},"modified":"2025-10-22T21:56:14","modified_gmt":"2025-10-23T01:56:14","slug":"vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\/","title":{"rendered":"Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sj\u00f6gren\u2019s Disease"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CAMBRIDGE, Mass., Oct.  22, 2025  (GLOBE NEWSWIRE) &#8212; Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for telitacicept in primary Sj\u00f6gren\u2019s disease. The study was conducted by Vor Bio\u2019s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331).<\/p>\n<p align=\"justify\">During the webcast, Vor Bio management, joined by Ronald van Vollenhoven, M.D., Ph.D., Professor of Rheumatology at Amsterdam University Medical Center, will review key efficacy and safety results from the trial.<\/p>\n<p align=\"justify\">\n        <strong>Webcast Details:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Date:<\/strong>\u00a0Tuesday, October 28, 2025<br \/><strong>Time:<\/strong>\u00a04:30 PM Eastern Time<\/p>\n<p align=\"justify\">\n        <strong>Access:<\/strong>\u00a0<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>Listen Only:<\/strong> Listeners can register for the webcast via this <a href=\"https:\/\/ir.vorbio.com\/events\/event-details\/primary-sjogrens-disease-acr-china-phase-3-data-update\" rel=\"nofollow\" target=\"_blank\">LINK<\/a><\/li>\n<li style=\"text-align:justify\">\n          <strong>Listen and Live Q&amp;A:<\/strong> Analysts or investors wishing to participate in the Q&amp;A session should use this <a href=\"https:\/\/register-conf.media-server.com\/register\/BI021686f7580b4c6dbf4e06373925257d\" rel=\"nofollow\" target=\"_blank\">LINK<\/a><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Replay:<\/strong>\u00a0A replay of the webcast will be available via the investor section of the Company\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wqHXX7xukQGxExrg263uh4daVWxQyQcdc38DPz5tIwHMSri6ta8nWAJ3wy89BoBQKRqwe4OTTCcqwBuaQjexyDNCu9fCPwf_lwY5BkR7Efo8yn7XktDqsX7lC5_emYmDGKJ_k5_0u7fSqM5hfkhphiH9AVfBIxlix8G65jD6haU=\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.vorbio.com\/events-presentations\/<\/a> approximately two hours after the call\u2019s conclusion and will remain available for a period of 30 days.<\/p>\n<p align=\"justify\">\n        <strong>About Vor Bio<\/strong><br \/>\n        <br \/>Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hPJ7jFGezWYnUFvvx37-v5LZneSnZqZYo0ftjKXquncUw967rCmgx1nf6t-JIcT-fFybgbZljZQ4AcM5xkeizQ==\" rel=\"nofollow\" target=\"_blank\">www.vorbio.com<\/a>.<\/p>\n<p>\n        <strong>Media &amp; Investor Contacts:<\/strong><br \/>\n        <br \/>Carl\u00a0Mauch<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PEIeelb0X3cQuTmIlqfVcigh3xXW2z12IKF-vUL22ArabU0MgRzoor6tfBsmZVTpVyTU5kuuLNm8enzyiOajxkPeKnl5gUjIYWuluo4DKK4=\" rel=\"nofollow\" target=\"_blank\">cmauch@vorbio.com<\/a><\/p>\n<p>Sarah Spencer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PDP43SgpKq--CJpJ5gOSxcCcnoD-UC6HjLIzuDs0G4a4syYU1Sy7F2hEn6rr8x0KJeLmCUwc1fWucSWn6QW-4GOQMTAVdA-C6ip53dg2T5s=\" rel=\"nofollow\" target=\"_blank\">investors@vorbio.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDI2OSM3MjA5NTcxIzIyMDIxNTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Mzg0NGYwMDAtN2I4ZS00ZjIzLTg3ZmItZGYwMGIxNzgyZWJlLTEyMTM3MDUtMjAyNS0xMC0yMi1lbg==\/tiny\/Vor-Biopharma.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) &#8212; Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for telitacicept in primary Sj\u00f6gren\u2019s disease. The study was conducted by Vor Bio\u2019s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331). During the webcast, Vor Bio management, joined by Ronald van Vollenhoven, M.D., Ph.D., Professor of Rheumatology at Amsterdam University Medical Center, will review key efficacy and safety results from the trial. Webcast Details: Date:\u00a0Tuesday, October 28, 2025Time:\u00a04:30 PM Eastern Time Access:\u00a0 Listen Only: Listeners can register for the webcast via this LINK Listen &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sj\u00f6gren\u2019s Disease&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-899061","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sj\u00f6gren\u2019s Disease - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sj\u00f6gren\u2019s Disease - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) &#8212; Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for telitacicept in primary Sj\u00f6gren\u2019s disease. The study was conducted by Vor Bio\u2019s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331). During the webcast, Vor Bio management, joined by Ronald van Vollenhoven, M.D., Ph.D., Professor of Rheumatology at Amsterdam University Medical Center, will review key efficacy and safety results from the trial. Webcast Details: Date:\u00a0Tuesday, October 28, 2025Time:\u00a04:30 PM Eastern Time Access:\u00a0 Listen Only: Listeners can register for the webcast via this LINK Listen &hellip; Continue reading &quot;Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sj\u00f6gren\u2019s Disease&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-23T01:56:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDI2OSM3MjA5NTcxIzIyMDIxNTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sj\u00f6gren\u2019s Disease\",\"datePublished\":\"2025-10-23T01:56:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\\\/\"},\"wordCount\":262,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU1MDI2OSM3MjA5NTcxIzIyMDIxNTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\\\/\",\"name\":\"Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sj\u00f6gren\u2019s Disease - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU1MDI2OSM3MjA5NTcxIzIyMDIxNTI=\",\"datePublished\":\"2025-10-23T01:56:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU1MDI2OSM3MjA5NTcxIzIyMDIxNTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU1MDI2OSM3MjA5NTcxIzIyMDIxNTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sj\u00f6gren\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sj\u00f6gren\u2019s Disease - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\/","og_locale":"en_US","og_type":"article","og_title":"Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sj\u00f6gren\u2019s Disease - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) &#8212; Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for telitacicept in primary Sj\u00f6gren\u2019s disease. The study was conducted by Vor Bio\u2019s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331). During the webcast, Vor Bio management, joined by Ronald van Vollenhoven, M.D., Ph.D., Professor of Rheumatology at Amsterdam University Medical Center, will review key efficacy and safety results from the trial. Webcast Details: Date:\u00a0Tuesday, October 28, 2025Time:\u00a04:30 PM Eastern Time Access:\u00a0 Listen Only: Listeners can register for the webcast via this LINK Listen &hellip; Continue reading \"Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sj\u00f6gren\u2019s Disease\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-23T01:56:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDI2OSM3MjA5NTcxIzIyMDIxNTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sj\u00f6gren\u2019s Disease","datePublished":"2025-10-23T01:56:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\/"},"wordCount":262,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDI2OSM3MjA5NTcxIzIyMDIxNTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\/","name":"Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sj\u00f6gren\u2019s Disease - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDI2OSM3MjA5NTcxIzIyMDIxNTI=","datePublished":"2025-10-23T01:56:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDI2OSM3MjA5NTcxIzIyMDIxNTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDI2OSM3MjA5NTcxIzIyMDIxNTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-to-host-webcast-on-late-breaking-china-phase-3-telitacicept-data-in-primary-sjogrens-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sj\u00f6gren\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/899061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=899061"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/899061\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=899061"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=899061"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=899061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}